Nephrotic Syndrome - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The nephrotic syndrome market size is expected to grow from USD 0.95 billion in 2025 to USD 1.05 billion in 2026 and is forecast to reach USD 1.73 billion by 2031 at 10.47% CAGR over 2026-2031. This report is segmented by Disease Type (Primary, Secondary), Modality (Treatment [Corticosteroids and More], Diagnosis), End User (Hospitals and Clinics, Specialty Nephrology Centers, Diagnostic Laboratories, and More), Distribution Channel (Hospital, Retail, Online Pharmacies, Others), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Nephrotic Syndrome Market Trends and Insights

Rising Diagnosis of Proteinuric Kidney Disease and Nephrotic Syndrome

Wider access to kidney biopsy is increasing diagnostic confirmation in areas that previously had limited capacity, allowing clinicians to distinguish nephrotic syndrome from other proteinuric conditions with greater confidence. South and Southeast Asia are important because clinical suspicion often outpaces biopsy-based confirmation, especially outside large referral hospitals. Proteinuria screening within hypertension and diabetes programs is also expanding the identification of patients with secondary nephrotic syndrome before advanced symptoms result in emergency care.

Earlier identification can bring patients into nephrology care before more severe kidney impairment develops and before supportive treatment is the only remaining option. The nephrotic syndrome market can therefore grow faster in these settings than incidence reports alone may suggest, as existing but untreated cases become visible to care systems. Delayed referral, uneven laboratory availability, and limited genetic testing still restrict the number of patients who receive a definitive diagnosis in lower-income settings.

Expansion of Targeted and Steroid-Sparing Therapies

The nephrotic syndrome market changed between 2024 and 2026 as products with new mechanisms advanced through regulatory review and gave nephrologists alternatives to broadly acting immunosuppression. The U.S. Food and Drug Administration approved 6 nephrology drugs across 4 indications in 2025, covering IgA nephropathy, lupus nephritis, C3 glomerulopathy, and chronic kidney disease progression. Vera Therapeutics received accelerated approval for TRUTAKNA, atacicept, for adults with primary IgA nephropathy in July 2026.

The product is a dual BAFF and APRIL inhibitor and adds another mechanism to treatment decisions for patients whose proteinuria is linked to IgA nephropathy. Mechanism-specific products extend therapeutic options across glomerular disorders that can present with nephrotic syndrome and encourage closer matching of treatment to disease biology. This development enlarges the addressable branded-treatment base beyond classical minimal change disease and raises the importance of specialist monitoring during initiation and follow-up.

Treatment Toxicity and Relapse-Driven Treatment Cycling

Corticosteroid-related adverse effects include growth suppression in children, hyperglycemia, infection susceptibility, and bone-density loss. These effects can lead to discontinuation or rotation of therapy, which makes treatment cycles less predictable for patients, caregivers, and treating teams. Calcineurin inhibitors are used in second-line pediatric and adult care, but their nephrotoxicity can limit dose and duration when kidney function is already impaired. Relapsed or refractory patients may move through several regimens before kidney damage narrows their options further and makes tolerability a central issue. This pattern raises encounter volumes without creating proportional treatment utilization because changes in treatment do not always sustain adherence or response. It also limits utilization growth for calcineurin inhibitor and alkylating-agent therapies in the nephrotic syndrome market.

Other drivers and restraints analyzed in the detailed report include:

• Podocyte-Directed and Non-Immunosuppressive Pipeline Innovation
• Greater Use of Molecular, Serological, and Biomarker-Led Diagnosis
• High Cost and Uneven Reimbursement for Rare-Disease Therapies

Segment Analysis

Primary nephrotic syndrome held 58.31% of the nephrotic syndrome market share in 2025, reflecting the established treatment base for conditions that are routinely identified in nephrology practice. It includes minimal change disease, membranous nephropathy, and FSGS, which have established care pathways using steroids, calcineurin inhibitors, and B-cell-directed treatment, although treatment selection changes with relapse pattern and response. Secondary nephrotic syndrome is projected to grow at a CAGR of 11.65% during 2026-2031. Growth is linked to approved therapies for IgA nephropathy and to diabetic nephropathy and lupus nephritis that can present with nephrotic-range proteinuria and need sustained proteinuria monitoring. The distinction between primary and secondary disease is becoming less clear at a molecular level as clinicians consider genetic susceptibility together with the immediate clinical trigger. APOL1 risk variants can increase FSGS progression risk in patients who also have secondary triggers, reinforcing the need for assessment that goes beyond the conventional disease label.

The 2025 KDIGO guideline places genetic testing within the steroid-resistant pathway. This approach can identify monogenic disease and change how some cases are classified, especially where the clinical presentation alone gives an incomplete answer. It may reclassify apparent primary cases as genetic-mediated and may also clarify secondary causes that would otherwise remain unclear in routine practice. The classification becomes more complex, but it better reflects the biology that guides therapy selection, monitoring needs, and referral decisions. Products approved for IgA nephropathy can be prescribed to eligible patients within the nephrotic syndrome population. This creates a practical connection between the primary and secondary categories at the prescribing level, even though the categories remain clinically useful. The Nephrotic syndrome industry is increasingly shaped by molecular classification alongside conventional disease labels, as this distinction can influence the path to targeted care.

Treatment held 81.24% of the nephrotic syndrome market size in 2025. This category includes corticosteroids, calcineurin inhibitors, B-cell-directed biologics, alkylating agents, antimetabolites, and complement-directed therapies, so it covers both long-established medicines and newer specialized options. Corticosteroids remain the initial treatment anchor in pediatric and adult care under KDIGO guidance. Their revenue contribution faces pressure as targeted branded products are introduced for defined glomerular conditions and as prescribers seek options that may reduce prolonged steroid exposure. Japan approved rituximab for refractory steroid-resistant nephrotic syndrome in September 2024. Japan then approved rituximab for non-refractory frequent-relapse or steroid-dependent pediatric disease in March 2025.

The diagnosis modality accounts for the remaining revenue and includes kidney biopsy and urinalysis, which remain important when clinicians need to define disease type and assess changes in proteinuria. Autoantibody measurement, urinary proteomic scoring, and noncoding RNA panels are opening recurring diagnostic pathways. These tools can support follow-up without relying only on biopsy-centered workflows and can provide additional information between major clinical assessments. Japan approved CellCept, mycophenolate mofetil, for refractory nephrotic syndrome in September 2025. The decision reflects the value of detailed urine-protein monitoring for defining refractory disease and selecting patients within a clearly documented care pathway. Further use of glomerular filtration rate testing and autoantibody panels could improve diagnosis revenue relative to 2025. The nephrotic syndrome market has room for both therapeutic and diagnostic innovation because treatment advances increase the need for reliable patient selection and continuing monitoring.

Complete Report Scope:

• By Disease Type
  • Primary Nephrotic Syndrome
  • Secondary Nephrotic Syndrome
• By Modality
  • Treatment
    • Corticosteroids
    • Calcineurin Inhibitors
    • B-Cell-Directed Therapies
    • Alkylating Agents
    • Antimetabolites
    • Complement-Directed Therapies
    • Other Therapies
  • Diagnosis
    • Urinalysis and Urine Protein-to-Creatinine Ratio
    • Blood Tests and Serum Albumin Assessment
    • Glomerular Filtration Rate Testing
    • Kidney Biopsy
    • Autoantibody and Complement Testing
    • Other Diagnostic Tests
• By End User
  • Hospitals and Clinics
  • Specialty Nephrology Centers
  • Diagnostic Laboratories
  • Dialysis Centers
  • Other End users
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.61% of the nephrotic syndrome market share in 2025. The region benefits from specialist nephrology capacity, payer coverage for renal rare diseases within defined criteria, and rapid drug approvals that give providers earlier access to newer treatment options. The United States approved 6 nephrology drugs in 2025. It added atacicept in 2026 for adults with primary IgA nephropathy. Canada contributes through provincial formulary decisions, while Mexico remains more weighted to generic corticosteroid and calcineurin inhibitor use. This mix means the region contains both mature specialty-treatment systems and settings where established maintenance medicines remain the main part of routine care.

Europe is the second-largest region, with Germany, France, and the United Kingdom serving as major treatment centers for patients who need specialist nephrology care. Regulatory progress has continued in the region, although cost-effectiveness review can slow formulary uptake and delay broad access after an authorization decision. Travere announced full U.S. Food and Drug Administration approval for FILSPARI in September 2024. North America and Europe are the first markets where specialized distribution and payer support are most developed. Their experience informs commercial strategies elsewhere because companies can observe the requirements for patient support, prescribing, and pharmacy coordination. The nephrotic syndrome market in these regions is supported by established rare-disease treatment infrastructure, but access still differs by national reimbursement decisions.

Asia-Pacific is projected to grow at a CAGR of 12.25% during 2026-2031. Japan authorized rituximab for steroid-resistant pediatric disease in September 2024 and for non-refractory steroid-dependent disease in March 2025. China approved iptacopan for IgA nephropathy in September 2025 and atrasentan in August 2025. India, South Korea, and Australia can benefit from improving workforce capacity, biopsy rates, and insurance coverage that can support at least part of the cost of targeted care. The Middle East, Africa, and South America remain smaller opportunities where reimbursement reform, local manufacturing agreements, and specialist infrastructure will matter for access. The nephrotic syndrome market in these geographies can expand when diagnosis is connected to a practical path for long-term treatment and monitoring.

List of Companies Covered in this Report:

• Alpine Immune Sciences, Inc.
• Apellis Pharmaceuticals, Inc.
• AstraZeneca
• Aurinia Pharmaceuticals Inc.
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Calliditas Therapeutics AB
• Chugai Pharmaceutical
• CSL Behring
• Dimerix Limited
• Dr. Reddy’s Laboratories
• Roche
• GlaxoSmithKline
• Ionis Pharmaceuticals
• Johnson & Johnson
• Kezar Life Sciences, Inc.
• Mallinckrodt plc
• Novartis
• Otsuka
• Pfizer
• Travere Therapeutics, Inc.
• Vera Therapeutics, Inc.
• Vertex Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support